Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients

D. Reyes, L. Salazar, E. Espinoza, C. Pereda, E. Castellón, R. Valdevenito, C. Huidobro, M. Inés Becker, A. Lladser, M. N. López, F. Salazar-Onfray

Resultado de la investigación: Article

36 Citas (Scopus)

Resumen

Background:Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. Tumour antigen-presenting cells induced immunological responses and increased melanoma patient survival. Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients.Methods:The lysate mix capacity, for inducing T-cell activation, was analysed by flow cytometry and Elispot. Delayed-type hypersensitivity (DTH) reaction against PCCL, frequency of CD8 + memory T cells (Tm) in blood and prostate-specific antigen (PSA) levels in serum were measured in treated patients.Results:The lysate mix induced functional mature DCs that were capable of activating PCCL-specific T cells. No relevant adverse reactions were observed. Six out of 14 patients showed a significant decrease in levels of PSA. DTH + patients showed a prolonged PSA doubling-time after treatment. Expansion of functional central and effector CD8 + Tm were detected.Conclusion:Treatment of CRPC patients with lysate-loaded TAPCells and CCH as an adjuvant is safe: generating biochemical and memory immune responses. However, the limited number of cases requires confirmation in a phase II clinical trial.

Idioma originalEnglish
Páginas (desde-hasta)1488-1497
Número de páginas10
PublicaciónBritish Journal of Cancer
Volumen109
N.º6
DOI
EstadoPublished - 17 sep 2013

Huella dactilar

Castration
Dendritic Cells
Prostatic Neoplasms
Vaccines
Neoplasm Antigens
Antigen-Presenting Cells
Prostate-Specific Antigen
Neoplasms
Hemocyanin
Delayed Hypersensitivity
T-Lymphocytes
Melanoma
Antigens
Phase II Clinical Trials
Flow Cytometry
Survival
Therapeutics
Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Citar esto

Reyes, D., Salazar, L., Espinoza, E., Pereda, C., Castellón, E., Valdevenito, R., ... Salazar-Onfray, F. (2013). Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. British Journal of Cancer, 109(6), 1488-1497. https://doi.org/10.1038/bjc.2013.494
Reyes, D. ; Salazar, L. ; Espinoza, E. ; Pereda, C. ; Castellón, E. ; Valdevenito, R. ; Huidobro, C. ; Inés Becker, M. ; Lladser, A. ; López, M. N. ; Salazar-Onfray, F. / Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. En: British Journal of Cancer. 2013 ; Vol. 109, N.º 6. pp. 1488-1497.
@article{d515c8c70b8742a4be221289206fbea9,
title = "Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients",
abstract = "Background:Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. Tumour antigen-presenting cells induced immunological responses and increased melanoma patient survival. Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients.Methods:The lysate mix capacity, for inducing T-cell activation, was analysed by flow cytometry and Elispot. Delayed-type hypersensitivity (DTH) reaction against PCCL, frequency of CD8 + memory T cells (Tm) in blood and prostate-specific antigen (PSA) levels in serum were measured in treated patients.Results:The lysate mix induced functional mature DCs that were capable of activating PCCL-specific T cells. No relevant adverse reactions were observed. Six out of 14 patients showed a significant decrease in levels of PSA. DTH + patients showed a prolonged PSA doubling-time after treatment. Expansion of functional central and effector CD8 + Tm were detected.Conclusion:Treatment of CRPC patients with lysate-loaded TAPCells and CCH as an adjuvant is safe: generating biochemical and memory immune responses. However, the limited number of cases requires confirmation in a phase II clinical trial.",
author = "D. Reyes and L. Salazar and E. Espinoza and C. Pereda and E. Castell{\'o}n and R. Valdevenito and C. Huidobro and {In{\'e}s Becker}, M. and A. Lladser and L{\'o}pez, {M. N.} and F. Salazar-Onfray",
year = "2013",
month = "9",
day = "17",
doi = "10.1038/bjc.2013.494",
language = "English",
volume = "109",
pages = "1488--1497",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

Reyes, D, Salazar, L, Espinoza, E, Pereda, C, Castellón, E, Valdevenito, R, Huidobro, C, Inés Becker, M, Lladser, A, López, MN & Salazar-Onfray, F 2013, 'Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients', British Journal of Cancer, vol. 109, n.º 6, pp. 1488-1497. https://doi.org/10.1038/bjc.2013.494

Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. / Reyes, D.; Salazar, L.; Espinoza, E.; Pereda, C.; Castellón, E.; Valdevenito, R.; Huidobro, C.; Inés Becker, M.; Lladser, A.; López, M. N.; Salazar-Onfray, F.

En: British Journal of Cancer, Vol. 109, N.º 6, 17.09.2013, p. 1488-1497.

Resultado de la investigación: Article

TY - JOUR

T1 - Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients

AU - Reyes, D.

AU - Salazar, L.

AU - Espinoza, E.

AU - Pereda, C.

AU - Castellón, E.

AU - Valdevenito, R.

AU - Huidobro, C.

AU - Inés Becker, M.

AU - Lladser, A.

AU - López, M. N.

AU - Salazar-Onfray, F.

PY - 2013/9/17

Y1 - 2013/9/17

N2 - Background:Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. Tumour antigen-presenting cells induced immunological responses and increased melanoma patient survival. Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients.Methods:The lysate mix capacity, for inducing T-cell activation, was analysed by flow cytometry and Elispot. Delayed-type hypersensitivity (DTH) reaction against PCCL, frequency of CD8 + memory T cells (Tm) in blood and prostate-specific antigen (PSA) levels in serum were measured in treated patients.Results:The lysate mix induced functional mature DCs that were capable of activating PCCL-specific T cells. No relevant adverse reactions were observed. Six out of 14 patients showed a significant decrease in levels of PSA. DTH + patients showed a prolonged PSA doubling-time after treatment. Expansion of functional central and effector CD8 + Tm were detected.Conclusion:Treatment of CRPC patients with lysate-loaded TAPCells and CCH as an adjuvant is safe: generating biochemical and memory immune responses. However, the limited number of cases requires confirmation in a phase II clinical trial.

AB - Background:Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. Tumour antigen-presenting cells induced immunological responses and increased melanoma patient survival. Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients.Methods:The lysate mix capacity, for inducing T-cell activation, was analysed by flow cytometry and Elispot. Delayed-type hypersensitivity (DTH) reaction against PCCL, frequency of CD8 + memory T cells (Tm) in blood and prostate-specific antigen (PSA) levels in serum were measured in treated patients.Results:The lysate mix induced functional mature DCs that were capable of activating PCCL-specific T cells. No relevant adverse reactions were observed. Six out of 14 patients showed a significant decrease in levels of PSA. DTH + patients showed a prolonged PSA doubling-time after treatment. Expansion of functional central and effector CD8 + Tm were detected.Conclusion:Treatment of CRPC patients with lysate-loaded TAPCells and CCH as an adjuvant is safe: generating biochemical and memory immune responses. However, the limited number of cases requires confirmation in a phase II clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84884592216&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.494

DO - 10.1038/bjc.2013.494

M3 - Article

C2 - 23989944

AN - SCOPUS:84884592216

VL - 109

SP - 1488

EP - 1497

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -